Titan Pharma in pact with AllianceRx Walgreens Prime to expand patient access to Probuphine
Titan Pharmaceuticals (NASDAQ:TTNP) entered a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime to expand patient access to its Probuphine six-month implant for the maintenance treatment of opioid use disorder (OUD) in eligible patients.
Titan expects the majority of Probuphine sales in the U.S. to be through the specialty pharmacy distribution model, where a specialty pharmacy, such as AllianceRx Walgreens Prime, carries inventory, directly handles patients' insurance billing and payment processes, and ships to the health care provider. The system is designed to facilitate patient access to treatment by streamlining the product ordering and fulfillment process.
Titan's strategic expansion of its network to include AllianceRx Walgreens Prime, one of the nation's largest specialty and home delivery pharmacies, is a key component of its focused commercialization strategy for Probuphine.
"For many people with OUD, the most effective treatment is a combination of counselling and medication-assisted treatment,” Tracey James, VP of pharmacy services at AllianceRx Walgreens Prime, said in a statement. “Our pharmacists use an integrated care management program to deliver comprehensive and collaborative care for patients."
Dane Hallberg, chief commercial officer of Titan, said AllianceRx Walgreens Prime has excellent relationships with third-party payers and a network of fulfillment sites that spans the entire country. “Its broad reach will significantly improve the ability of OUD patients to gain access to long-term maintenance treatment with Probuphine."